For decades, opioids have been the go-to medication for managing post-operative and other types of pain. However, the tide is turning as the devastating consequences of opioid addiction become increasingly clear. Athletes, known for pushing their bodies to the limit, are at the forefront of this shift, seeking out innovative, non-opioid solutions to manage pain after surgery and expedite healing. Their experiences are raising public awareness - and investor attention - about alternative treatment options and paving the way for a future where powerful painkillers are not the only answer.
A few public companies to evaluate now to get exposure to the future of pain treatments are
Dire Need to Phase Out Opioids
The opioid crisis in the
The stories of legendary athletes like Hall of Fame quarterback
The tragic case of NHL left winger
With the growing awareness of these dangers, the "revolving door" of readily available prescription pain medication is shutting. Pro teams are being forced to re-evaluate their approach to managing player injuries. This shift presents a crucial opportunity - a chance to embrace innovative, non-opioid solutions that prioritize player health and well-being.
Next-Gen Alternatives are Investment Opportunities
SofPulse® is a gentle pulsed electromagnetic field (PEMF) therapy, where targeted ultra-low microcurrents (~1,000x weaker than those emitted by a mobile phone) are transmitted to damaged tissue, helping to reduce swelling and speed up the natural recovery process. As a viable non-opioid pain reduction solution, it offers cost-effective treatments while reducing the risk of opioid dependency and addiction. SofPulse®' is non-invasive and its ease of use makes it a convenient option for at-home or clinical use.
The FDA has cleared SofPulse® for post-operative pain and edema, indicating that it has met stringent safety and efficacy standards set by regulatory authorities. Endonovo has already established distribution channels in the
SofPulse® international distribution into
Endonovo has announced plans to expand international distribution to Central and
The reduction in pain provided by SofPulse® has been validated significantly through clinical studies and research where results have proven its efficacy and effectiveness in reducing pain and swelling, a claim many medical device manufacturers cannot make. Simply, the FDA doesn't require as stringent human data for medical devices as they do for drugs. SofPulse® targets pain reduction and its PEMF technology promotes faster recovery with fewer side effects and less medication. Its therapeutic approach sets it apart from devices that simply mask or block pain, making it a comprehensive option for post-operative care.
SofPulse is the only FDA-cleared, non-invasive medical device offering round-the-clock, continuous pain therapy. SofPulse is programmed to administer its pain-relieving PEMF therapy continually to the site of the pain.
Most medical companies, much less a small one like Endonovo with an extremely undervalued
However, Endonovo stands tall with its clinical database. To date, there have been a total of 14 PEMF studies showing efficacy utilizing SofPulse® and over 20,000 uses with no known side effects. SofPulse® works on a cellular level to remove the cause of the pain, thereby reducing edema and inflammation and accelerating recovery through enhanced blood flow and remodeling.
To lend a little color, consider a double-blind, placebo-controlled, randomized study that evaluated the impact of SofPulse® on pain and narcotic use after breast reduction and breast augmentation procedures. The results, which were published in Plastic Reconstruction Surgery, were highlighted by a 57% decrease in mean pain scores at one hour post-procedure and 300% decrease in mean pain scores at five hours and a 275% reduction of inflammation and swelling at 18 hours after surgery. The drop in pain resulted in a 2.2X-fold reduction in narcotic use in active patients.
In combination with Endonovo's comprehensive telehealth platform, the company is positioned as a market leader with a solid competitive edge. By expanding its distribution channels and focusing on key markets, SofPulse® is positioned to revolutionize pain management and post-operative care on a global scale, benefiting patients, healthcare providers, and investors alike.
PEMF Therapy: A Growing Trend in Pain Management
PEMF is an emerging approach gaining traction in the realm of pain management. PEMF therapy has attracted the attention of some high-profile figures, including athletes like NBA Hall of Famer
There is little to no controversy about the safety of PEMF treatments. Lending further evidence, the
Other Non-PEMF treatments and devices can be invasive, requiring injections or catheters, with limited pain reduction results and durations of use. They often have multiple contraindications, including increased risk of mortality and or death. Most non-opioid devices only offer temporary pain relief and lack FDA approval for reducing edema and swelling. PEMF solutions, like the one offered by SofPulse®, is therapeutic and by addressing the biochemical root of pain, offer a superior, drug-free solution for optimal pain and inflammation management. Additionally, SofPulse® is an excellent non-pharmalogical pain management solution for patients with a history of opioid abuse or those susceptible to such abuse.
Adoption of Alternate Therapies
Exparel, a long-acting local anesthetic administered through injection during surgery, is another non-opioid option gaining popularity. Exparel provides targeted pain relief at the surgical site, minimizing the need for systemic opioids. Professional golfer
Spinal cord stimulation (SCS) is a more invasive, but highly effective technique for chronic pain management. A device implanted near the spinal cord delivers mild electrical pulses that disrupt pain signals before they reach the brain. An article published in Nature in
Quell® Fibromyalgia is a thin wearable medical device that is inserted into a soft band, a disposable electrode is attached and then the band is placed on the upper calf. It is easy to use, wear and forget technology. The device comfortably stimulates sensory nerves to help relieve the symptoms of fibromyalgia without significant side effects.
The growing adoption of these alternative therapies is not just about individual recovery. It's about raising public awareness and challenging the perception of opioids as the only viable solution for post-operative pain. Seeing pro-level athletes, like
The end of the opioid crisis begins in the doctor's office followed by louder megaphones trumpeting stories of successful recovery without relying on any powerful painkillers. The day is coming soon where managing pain doesn't come at the cost of addiction. And just like any other major shift in a sector, there are going to be some big winners.
Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of ENDV or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://wallstreetpr.com/disclaimer/. WallStreetPR.com has been compensated for content distribution services on ENDV by a 3rd party. We own zero shares of ENDV. WallStreetPR.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of WallStreetPR.com is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the
Media Contact
Company
Contact Person:
Email: steve@wallstreetpr.com
Address:info@edm.media
City:
State:
Country:
Website: https://www.wallstreetpr.com/
.
(C) 2024 M2 COMMUNICATIONS, source